A previous study showed that interleukin-1β, released by TAMs, might enhance the presence of β-catenin through GSK3β phosphorylation in colon cancer cells, thereby preventing the β-catenin destruction complex from performing its normal functions (17). Here, GSK3B is linked to malignant colon neoplasm.